Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 137-141

  Papaparaskevas, Joseph ^a   Pantazatou, Angeliki ^b   Katsandri, Anastasia ^a,b   Houhoula, Dimitra P ^a   Legakis, Nicholas J ^a   Tsakris, Athanassios ^a   Avlamis, Athina ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Anaerobes; Bacteroides spp.; Epidemiology; Metronidazole; Prevotella spp.; Susceptibility

Indexed keywords

CEFOXITIN; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES; BACTEROIDES CAPILLOSUS; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; EPSILOMETER TEST; EUROPE; GRAM NEGATIVE ANAEROBIC BACTERIA; GREECE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA; PREVOTELLA BIVIA; PREVOTELLA ORALIS; SPECIES DIVERSITY;

ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEROIDACEAE INFECTIONS; BACTEROIDES; BACTEROIDES INFECTIONS; DRUG RESISTANCE, BACTERIAL; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVOTELLA; QUINOLINES;

EID: 45749091754     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn134     Document Type: Article

References (14)

1. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9: 475-88.
2. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
3. Ackermann G, Schaumann R, Pless B et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32.
4. Citron DM, Goldstein EJC, Merriam CV et al. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: 2819-28.
5. Goldstein EJC, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-55.
6. Wybo I, Pierard D, Verschraegen I et al. Third Belgian multicenter survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007; 59: 132-9.
7. Jousimies-Somer HR, Summanen P, Citron DM et al. Wadsworth - KTL Anaerobic Bacteriology Manual, 6th edn. Belmont, CA: Star Publishing Company, 2002; 81-132.
8. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Testing of Anaerobic Bacteria - Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
9. Betriu C, Rodríguez-Avial I, Gomez M et al. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002). Diagn Microbiol Infect Dis 2005; 53: 221-3.
10. Golan Y, McDermott LA, Jacobus NV et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003; 52: 208-13.
11. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis group: Report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007; 51: 1649-55.
12. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-7.
13. Miyamae S, Ueda O, Yoshimura F et al. A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 2001; 45: 3341-6.
14. Katsandri A, Avlamis A, Pantazatou A et al. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Diagn Microbiol Infect Dis 2006; 55: 231-6.